Carmen Fernández-Met
zler, Ph.D. graduated from MIT with a S.B. in Chemistry. After earning her Ph.D. in Chemistry from the University of Pennsylvania, Dr. Fernández-Metzler joined the Department of Drug Metabolism at Merck & Co. in West Point, PA where she was a group leader, scientific mentor, and project team representative over the course of more than 18 years. Dr. Fernández-Metzler was responsible for developing and applying mass spectrometric and ligand binding analytical approaches to support discovery and development of small molecule and biologic drug candidates. In the fall of 2010, Dr. Fernández-Metzler left Merck to become President of PharmaCadence Analytical Services, LLC.
Richard C. King, Ph.D. graduated from SUNY College of Environmental Science and Forestry at Syracuse with a B.S. in Chemistry. After earning his Ph.D. in Analytical Chemistry from Drexel University, Dr. King joined the Department of Drug Metabolism at Merck & Co. where he worked in Preclinical Drug Metabolism for 14 years with a focus on bioanalysis and new technology development and implementation. In the fall of 2008, he became one of the founding members of PharmaCadence Analytical Services, LLC. Dr. King’s research interests cover a number of key areas in quantitative analysis by mass spectrometry including: ion formation mechanisms, ion chemistry, automation, separation science, and data processing. He is regularly engaged in leading training courses on the use of time-of-flight and triple quadrupole mass spectrometers for bioanalysis.
